JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Apellis Pharmaceuticals Inc

Fechado

SetorSaúde

28.6 1.89

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.02

Máximo

28.89

Indicadores-chave

By Trading Economics

Rendimento

50M

-42M

Vendas

12M

178M

Margem de lucro

-23.615

Funcionários

705

EBITDA

50M

-30M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+28.14% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

3.6B

Abertura anterior

26.71

Fecho anterior

28.6

Sentimento de Notícias

By Acuity

34%

66%

108 / 371 Ranking em Healthcare

Apellis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de out. de 2025, 20:49 UTC

Ganhos

Correction to Thermo Fisher Article on Oct. 22

23 de out. de 2025, 23:51 UTC

Conversa de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 de out. de 2025, 23:37 UTC

Conversa de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 de out. de 2025, 22:58 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de out. de 2025, 22:57 UTC

Conversa de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -2-

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 de out. de 2025, 22:17 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 de out. de 2025, 21:41 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 de out. de 2025, 21:05 UTC

Ganhos

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de out. de 2025, 20:35 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 de out. de 2025, 20:28 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 de out. de 2025, 20:15 UTC

Conversa de Mercado
Ganhos

Global Commodities Roundup: Market Talk

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Adj EPS $1.71

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Sales $5.52B

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q EPS $1.67

23 de out. de 2025, 20:09 UTC

Ganhos

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 de out. de 2025, 20:07 UTC

Ganhos

Blackstone Looks to IPOs for Investment Exits -- Update

23 de out. de 2025, 20:05 UTC

Ganhos

Intel 3Q Gross Margin 38.2% >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 de out. de 2025, 20:04 UTC

Ganhos

Intel: 4Q Guidance Excludes Altera >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Sees 4Q Adj EPS 8c >INTC

Comparação entre Pares

Variação de preço

Apellis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

28.14% parte superior

Previsão para 12 meses

Média 36.06 USD  28.14%

Máximo 60 USD

Mínimo 18 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Apellis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

10

Comprar

6

Manter

1

Vender

Sentimento

By Acuity

108 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat